Group 1 - Zymeworks Inc. reported a quarterly loss of $0.26 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.27, and an improvement from a loss of $0.76 per share a year ago, resulting in an earnings surprise of 3.70% [1] - The company posted revenues of $19.24 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 16.93%, but showing significant growth from $7 million in the same quarter last year [2] - Over the last four quarters, Zymeworks has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Group 2 - The stock has added about 0.7% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $12.09 million, and for the current fiscal year, it is -$1.24 on revenues of $92.54 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the "Company"), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that its Board of Directors has authorized a Share Repurchase Program under which the Company may repurchase up to $60.0 million of the Company's outstanding common stock, par value $0.00001 per share. Zymework ...

VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the "Company"), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that its Board of Directors has authorized a Share Repurchase Program under which the Company may repurchase up to $60.0 million of the Company's outstanding common stock, par value $0.00001 per share. Zymework ...

BTIG Virtual Biotechnology Conference: Zymeworks' management will participate in virtual one-on-one meetings and a fireside chat on Tuesday, August 6 at 4:00 pm Eastern Time (ET). Wedbush PacGrow Healthcare Conference: Zymeworks' management will participate a panel discussion titled "ADCs and Old Lace: Antibody Drug Conjugates" taking place on August 14, between 8:45 – 9:25 am ET, and will participate in one-on-one meetings on August 13-14 in New York, NY. VANCOUVER, British Columbia, July 30, 2024 (GLOBE N ...

BTIG Virtual Biotechnology Conference: Zymeworks' management will participate in virtual one-on-one meetings and a fireside chat on Tuesday, August 6 at 4:00 pm Eastern Time (ET). Wedbush PacGrow Healthcare Conference: Zymeworks' management will participate a panel discussion titled "ADCs and Old Lace: Antibody Drug Conjugates" taking place on August 14, between 8:45 – 9:25 am ET, and will participate in one-on-one meetings on August 13-14 in New York, NY. VANCOUVER, British Columbia, July 30, 2024 (GLOBE N ...

VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. "I am very pleased to be joining Zymeworks as the Company plans for many important mileston ...

VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. "After an extensive search, we are delighted to have Leone Patterson join us at this exciti ...

Cautionary Note Regarding Forward-Looking Statements Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looki ...

Zymeworks' development of its product candidates; the timing and status of ongoing and future studies and the related data; expectations and timing regarding future regulatory filings and approvals; the timing of and results of interactions with regulators; potential safety profile and therapeutic effects of zanidatamab and Zymeworks' other product candidates; the commercial potential of technology platforms and product candidates and other information that is not historical information. When used herein, w ...

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provid ...